Clinical Trial Results (OBGYN)
Clinical trials remain an essential part of our development process, providing invaluable insights into the safety, efficacy, and potential benefits or risks of our novel transdermal pain medicine. Recently, a key study was conducted focusing on the use of our product, specifically on post-episiotomy pain in obstetrical patients. In this study, 48 women aged 18 to 39, who underwent a vaginal delivery with an episiotomy, were analyzed for pain reduction after applying our flavonoid-terpenoid NN65-26 fortified topical spray. Post-episiotomy pain was assessed using the Visual Analog Scale (VAS). By the end of the treatment course, progress in wound healing was also analyzed. The results of this study were extremely promising: the average pain score in the patients of the Relivra treatment group was significantly lower compared to the placebo group, with pain reduced by 42% (P<0.001). Notably, treatments with our plant-flavonoid peptide coupled with impregnated sol-gels caused a significant decrease in post-episiotomy pain. Further, the advanced biocatalyst topical formulation was observed to promote wound healing. Importantly, safety assessments showed that the topical application of naringin did not result in any skin irritation. It also did not diffuse into breast milk, even after topical applications, thereby ensuring the safety of both the mother and the breastfeeding infant. The study concluded that our naringin-based spray is an effective and safe remedy for post-episiotomy pain and should be added to the obstetrical armamentarium. This study, along with our ongoing research, continues to validate the efficacy and safety of our novel topical pain medicine, opening new avenues for pain management.
Clinical Trial Results (Orthopedics and Rehabilitation)
Our clinical trials in orthopedics and rehabilitation have also shown significant benefits: Our product has demonstrated a substantial reduction in rehabilitation time, with patients recovering 40% faster than usual. This is a significant improvement, as it not only reduces the burden on patients but also decreases the overall cost of care.Pain reduction was also superior compared to oral medication alone. This is particularly noteworthy as pain is a major factor that can hinder recovery and rehabilitation. By providing superior pain management, our product can help patients return to their normal activities more quickly.Functional recovery was achieved in half the usual time, further demonstrating the effectiveness of our product in promoting faster recovery. This is a key advantage, as faster functional recovery can significantly improve the quality of life for patients. Moreover, our product has shown a significant impact on reducing hospital readmission rates. Our novel pain formula and delivery system has shown remarkable results in reducing hospital readmission rates, a significant issue in healthcare due to its high costs for both providers and insurance companies. With a reduction in one-month readmission by 70% and a staggering 95% decrease in three-month readmission, our product can result in substantial cost savings. Considering that the average cost of readmission within 30 days after discharge is estimated at $13,800 per patient, the reduction in readmission rates achieved by our product can lead to significant savings. For instance, a healthcare provider or insurer who caters to 1,000 patients per year could potentially save up to $9.66 million annually on one-month readmissions alone, thanks to our product. According to 2020 FSMB Census, there is 20,000 OBGYN, Orthopedic Trauma and Rehabilitation providers with up to a 1000 patients in the US, which translates into over $200 billion in savings annually. Furthermore, given the enormous reduction in three-month readmission rates, the potential cost savings over a longer time horizon would be even greater. This makes our product not only a tool for improved patient outcomes but also a financially beneficial choice for healthcare providers and insurance companies.
In conclusion, by reducing pain, accelerating recovery, and significantly decreasing readmission rates, our novel topical pain medicine presents a compelling cost-effective solution in the healthcare industry. Our product possesses the potential to revolutionize pain management, offering both improved patient care and substantial cost savings for healthcare providers and insurers.